Research Topics
| Robert E RatnerSummaryCountry: USA Publications
| Collaborators
|
Detail Information
Publications
An update on the Diabetes Prevention ProgramRobert E Ratner
MedStar Research Institute, Hyattsville, Maryland, USA
Endocr Pract 12:20-4. 2006..CONCLUSION: The DPP showed that both metformin and intensive lifestyle modifications effectively delayed or prevented the development of diabetes in a cost-effective manner...
Pramlintide: A new tool in diabetes managementLaura L Want
Curr Diab Rep 6:344-9. 2006..In clinical use, pramlintide reduces postprandial glycemic excursions and improves A(1c) without the weight gain and increased risk of hypoglycemia typically seen with intensification of diabetes therapy...- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesRobert Ratner
MedStar Health Research Institute, Hyattsville, MD, USA
Cardiovasc Diabetol 10:22. 2011..Keywords: GLP-1 receptor agonist, diabetes, cardiovascular safety... - Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096)R Ratner
MedStar Health Research Institute, Hyattsville, MD, USA
Diabetes Obes Metab 13:1142-8. 2011..This study examined the effect of postprandial vs. preprandial insulin glulisine on weight gain and glycaemic control in type 2 diabetes patients taking basal insulin... - Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetesRobert E Ratner
MedStar Research Institute, Hyattsville, MD 20783, USA
Diab Vasc Dis Res 4:214-21. 2007..The clinical development of tesaglitazar is no longer continuing; its effects on the glucose and lipid abnormalities of type 2 diabetes suggest that the concept of dual PPARalpha/gamma agonism is worthy of further investigation... 
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristicsRobert E Ratner
MedStar Research Institute, Washington, DC, USA
Am Heart J 156:1074-9. 2008..Rosiglitazone, a thiazolidinedione, has effects on insulin sensitivity and cardiovascular risk factors that may favorably impact the progression of coronary atherosclerosis...- Prevention of type 2 diabetes in women with previous gestational diabetesRobert E Ratner
MedStar Research Institute, 6495 New Hampshire Ave, Hyattsville, MD 20783, USA
Diabetes Care 30:S242-5. 2007 - Treatment recommendations for prediabetesRobert E Ratner
MedStar Health Research Institute, 6525 Belcrest Road, Suite 700, Hyattsville, MD 20782, USA
Med Clin North Am 95:385-95, viii-ix. 2011..Lifestyle intervention is universally accepted as the primary intervention strategy. Secondary intervention is advocated in high-risk individuals or in the absence of a clinical response to lifestyle modification... - Incretin-based therapies for type 2 diabetes: clinical utilityRobert Ratner
MedStar Research Institute, Hyattsville, MD 20783, USA
Endocrinol Metab Clin North Am 35:12-6; discussion 17-19. 2006 - Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventionsRobert E Ratner
MedStar Research Institute, Hyattsville, Maryland 20783, USA
J Clin Endocrinol Metab 93:4774-9. 2008..A past history of gestational diabetes mellitus (GDM) confers a very high risk of postpartum development of diabetes, particularly type 2 diabetes... - Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetesRobert E Ratner
MedStar Research Institute, Washington, DC, USA
Diabetes Technol Ther 4:51-61. 2002.... - Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experienceMihriye Mete
MedStar Health Research Institute, Hyattsville, MD 20782, USA
J Diabetes Complications 25:362-7. 2011..This post hoc analysis from the Stop Atherosclerosis in Native Diabetics Study examines the role of baseline glycemia in achieving standard and aggressive targets and outcomes after 36 months... - Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trialBarbara V Howard
MedStar Research Institute, 6495 New Hampshire Ave, Suite 201, Hyattsville, MD 20783, USA
JAMA 299:1678-89. 2008..Individuals with diabetes are at increased risk for cardiovascular disease (CVD), but more aggressive targets for risk factor control have not been tested... - Combination pharmacotherapy with incretins: what works best and when?Rebecca K Over
MedStar Research Institute, 6495 New Hampshire Avenue, Suite 201, Hyattsville, MD 20783, USA
Curr Diab Rep 8:361-7. 2008..New incretin-based approaches offer promising new strategies for treating T2DM by recruiting new, physiologically based mechanisms of action for glucoregulation in the context of a favorable safety profile... - Differential effects of oral hypoglycemic agents on glucose control and cardiovascular riskGabriel I Uwaifo
Georgetown University College of Medicine, Washington, District of Columbia 20003, USA
Am J Cardiol 99:51B-67B. 2007..This review presents the available data on the effects of the various OHAs on cardiovascular risk surrogates and actual events in retrospective and prospective study design settings... - Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination SurveyHelaine E Resnick
Department of Epidemiology and Statistics, MedStar Research Institute, 6495 New Hampshire Ave, Suite 201, Hyattsville, MD 20783
Diabetes Care 29:531-7. 2006..To estimate the proportion of U.S. adults with diabetes who meet American Diabetes Association (ADA) clinical practice recommendations... - Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?Shannon D Sullivan
Department of Endocrinology, Washington Hospital Center, 110 Irving Street, NW, Suite 2A 72, Washington, DC 20010, USA
Curr Diab Rep 11:91-8. 2011..Taken together, we recommend that prediabetic patients undergo intensive lifestyle intervention, with the addition of pharmacotherapy based on the presence of specific features of the metabolic syndrome, for diabetes prevention... - The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular diseaseGabriel I Uwaifo
MedStar Research Institute, Hyattsville, Maryland 20783, USA
Am J Med 115:12S-19S. 2003..These effects remain to be substantiated by the results of large outcomes studies to evaluate the impact of glycemic control and reversal of insulin resistance on cardiovascular events... - Approach to the patient with prediabetesVanita R Aroda
Med Star Clinical Research Center, 650 Pennsylvania Avenue SE, Washington, DC 20003, USA
J Clin Endocrinol Metab 93:3259-65. 2008..This article will review some of the issues surrounding the identification and treatment of prediabetes, with an interpretation of the available data to help guide management... - Impact of computer-generated personalized goals on HbA(1c)Claresa S Levetan
Department of Internal Medicine, Division of Endocrinology, Washington Hospital Center, Washington, DC, USA
Diabetes Care 25:2-8. 2002..We set forth to evaluate the impact of a system that provides uniquely formatted and personalized reports of diabetes status and goals on changes in HbA(1c) levels... - Coronary heart disease risk equivalence in diabetes depends on concomitant risk factorsBarbara V Howard
MedStar Research Institute, Washington, DC, USA
Diabetes Care 29:391-7. 2006..Diabetes has been defined as a coronary heart disease (CHD) risk equivalent, and more aggressive treatment goals have been proposed for diabetic patients... - Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS)Marie Russell
Phoenix Indian Medical Center, Phoenix, AZ, USA
Am Heart J 152:867-75. 2006.... - Novel pharmacologic agents for type 2 diabetesGabriel I Uwaifo
Georgetown University College of Medicine, Washington DC 20003, USA
Endocrinol Metab Clin North Am 34:155-97. 2005..There is reason to expect that despite the growing burden of diabetes worldwide, we will be better equipped to manage it and its comorbidities and prevent its onset and possibly even cure it... - Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesRalph A DeFronzo
Division of Diabetes, University of Texas Health Science Center, San Antonio, TX, USA
Diabetes Care 28:1092-100. 2005..CONCLUSIONS: Exenatide was generally well tolerated and reduced HbA(1c) with no weight gain and no increased incidence of hypoglycemia in patients with type 2 diabetes failing to achieve glycemic control with metformin... - Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week studySherwyn L Schwartz
Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
Clin Ther 30:858-67. 2008..The aim of this study was to examine the glucose-lowering effect of exenatide over 24 hours in patients with type 2 diabetes with inadequate glycemic control using metformin, with or without a thiazolidinedione (TZD)... - Managing people at high risk for diabetesWilliam H Herman
Ann Intern Med 144:66-7; author reply 67-8. 2006 - Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention programAllan F Moore
Center for Human Genetic Research, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
Diabetes 57:2503-10. 2008.... - Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention programWilliam H Hernan
The Diabetes Prevention Program Coordinating Center, Biostatistics Center, George Washington University, Rockville, Maryland 20852, USA
Diabetes Care 26:36-47. 2003..To describe the costs of the Diabetes Prevention Program (DPP) interventions to prevent or delay type 2 diabetes... - Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathyW Kline Bolton
Department of Medicine, University of Virginia Health System, Charlottesville, Va 2908 0133, USA
Am J Nephrol 24:32-40. 2004..This study was undertaken to determine if pimagedine ameliorates nephropathy in type 1 (insulin-dependent) diabetes mellitus... - Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study)Georgios I Papaioannou
Cardiology Division, Henry Low Heart Center, Hartford Hospital, and University of Connecticut School of Medicine, Farmington, USA
Am J Cardiol 94:294-9. 2004..In addition, microalbuminuria is an independent predictor of endothelial dysfunction in asymptomatic patients with DM, especially in the absence of hormone replacement therapy... - Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD studyFrans J Th Wackers
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Diabetes Care 27:1954-61. 2004..To assess the prevalence and clinical predictors of silent myocardial ischemia in asymptomatic patients with type 2 diabetes and to test the effectiveness of current American Diabetes Association screening guidelines... - The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose toleranceWilliam H Herman
University of Michigan Health System, Ann Arbor, Michigan, USA
Ann Intern Med 142:323-32. 2005..LIMITATIONS: Simulation results depend on the accuracy of the underlying assumptions, including participant adherence. CONCLUSIONS: Health policy should promote diabetes prevention in high-risk individuals... - Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imagingGeorgios I Papaioannou
Henry Low Heart Center, Cardiology Division, Hartford Hospital, CT 06102, USA
J Nucl Cardiol 13:362-8. 2006.... - An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetesRonald T Ackermann
Department of Medicine, Indiana University School of Medicine, 250 University Blvd, Suite 122, Indianapolis, IN 46202, USA
Diabetes Care 29:1237-41. 2006..We explored whether this intervention could be offered in a way that allows return on investment for private health insurers while remaining attractive for consumers, employers, and Medicare... - Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) studyFrans J Th Wackers
Yale University School of Medicine, Section of Cardiovascular Medicine, 333 Cedar St Fitkin 3, New Haven, CT 06520, USA
Diabetes Care 30:2892-8. 2007..The purpose of this study was to assess whether the prevalence of inducible myocardial ischemia increases over time in patients with type 2 diabetes... - Impact of computer-generated personalized goals on cholesterol loweringClaresa S Levetan
Department of Internal Medicine, Lankenau Hospital, Wynnewood, PA 19096, USA
Value Health 8:639-46. 2005..This randomized, controlled trial was designed to evaluate the impact of a system that provides uniquely formatted laboratory results to patients with CVD on their changes in LDL-C levels...